Latest News
-
Friday - May 3, 2013
Not intended for UK Media
Bayer Provides Update on Phase II/III Trial of BAY 86-6150 » more
-
Friday - May 3, 2013
Board Member Dr. Rüdiger Scheitza to retire
Bayer CropScience announces organizational and personnel changes at the Excecutive Committee » more
-
Thursday - May 2, 2013
Focus on optimal face protection
Bayer polycarbonate improves firefighter safety
Specialty plastic satisfies stringent requirements for protective helmets » more
-
Tuesday - April 30, 2013
Bayer MaterialScience To Sell Polyester Resins Businesses to Stepan » more
-
Monday - April 29, 2013
Bayer CropScience on the announcement by the EU Commission:
Restrictions in use of neonicotinoid-containing products is a set-back for European agriculture
Commission’s plan will not have a positive impact on bee health » more
-
Monday - April 29, 2013
Not intended for UK media - Strategic expansion of Women’s Health business:
Bayer to acquire Conceptus, Inc.
Adds Essure®, the only non-surgical permanent birth control method, to Bayer’s contraception portfolio » more
-
Friday - April 26, 2013
Annual Stockholders' Meeting 2013 » more
-
Thursday - April 25, 2013
First quarter of 2013:
Bayer: Life Sciences off to a good start in anniversary year
New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed » more
-
Thursday - April 25, 2013
Bayer helps victims of earthquake in China
Monetary and material donations totaling around EUR 1.1 million » more
-
Thursday - April 25, 2013
World Malaria Day 2013:
Innovative solutions from Bayer CropScience to combat malaria
Vector control portfolio protected millions of lives in 2012 / Important role of public-private partnerships and research collaborations / Training and education of local communities » more
-
Tuesday - April 23, 2013
Bayer CropScience and KeyGene enter into research agreement to develop improved crop varieties – initial focus on wheat » more
-
Thursday - April 18, 2013
Makrolon® multi UV 3/16-20: triple-wall sheet with optimized properties
Successor of Multi UV 3/16-16 has excellent surface quality » more
-
Tuesday - April 16, 2013
Bayer CropScience and Monsanto Enter into Cross-Licensing Agreements for Next-Generation and Enabling Technologies
Agreements Create More Options for Farmers / Expanded Market Opportunities for Next-Generation Technologies » more
-
Tuesday - April 16, 2013
High-performance plastic sheets chosen for new greenhouse:
Bayer material for reconstruction project in Japan’s disaster area » more
-
Tuesday - April 16, 2013
Not intended for U.S. and UK Media
First Patient Enrolled in Global Phase III Program Evaluating Bayer’s Amikacin Inhale in Intubated and Mechanically Ventilated Patients with Gram-negative Pneumonia
Treatments to complement current standard of care urgently needed as morbidity and mortality is significant in this patient population » more
-
Wednesday - April 10, 2013
Gentle conditioning and styling for damaged hair
Bayer raw materials enhance appearance and structure » more
-
Wednesday - April 10, 2013
Immunotherapies against cancer:
Bayer HealthCare to broaden strategic alliance with German Cancer Research Center
Joint immunotherapy research laboratory at the National Center for Tumor Diseases (NCT) in Heidelberg / Operations at the joint laboratory scheduled to start in the middle of 2013 / Additional investments of up to €3 million per year » more
-
Monday - April 8, 2013
Not intended for U.S. and UK Media
U. S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications » more
-
Friday - April 5, 2013
Not intended for U.S. and UK Media - 104th Annual Meeting American Association for Cancer Research
Bayer to Present New Data on Growing Oncology Pipeline
New Preclinical and Early Clinical Data Evaluating Innovative Compounds in Drug Development / Numerous Oral and Poster Presentations Highlight Bayer’s Advancing Oncology Portfolio » more
-
Thursday - April 4, 2013
Not intended for US or UK use - AMWC Congress 2013
Bayer’s ATX-101 significantly and sustainably reduces unwanted fat under the chin
90% of patients maintained treatment success in two year follow up / Phase I pharmacokinetic data shows no clinically significant impact on lipid levels / Open-label study data from US trial to be presented at Innovation Session » more
Copyright @ Bayer AG